- Home
- BIRD vs SCYX Comparison
BIRD vs SCYX Comparison
Compare BIRD & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- SCYX
- Stock Information
- Founded
- BIRD 2015
- SCYX 1999
- Country
- BIRD United States
- SCYX United States
- Employees
- BIRD N/A
- SCYX N/A
- Industry
- BIRD Apparel
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- SCYX Health Care
- Exchange
- BIRD Nasdaq
- SCYX Nasdaq
- Market Cap
- BIRD 50.7M
- SCYX 40.9M
- IPO Year
- BIRD 2021
- SCYX 2014
- Fundamental
- Price
- BIRD $5.15
- SCYX $0.97
- Analyst Decision
- BIRD Buy
- SCYX
- Analyst Count
- BIRD 3
- SCYX 0
- Target Price
- BIRD $12.00
- SCYX N/A
- AVG Volume (30 Days)
- BIRD 68.5K
- SCYX 98.2K
- Earning Date
- BIRD 05-08-2025
- SCYX 05-07-2025
- Dividend Yield
- BIRD N/A
- SCYX N/A
- EPS Growth
- BIRD N/A
- SCYX N/A
- EPS
- BIRD N/A
- SCYX N/A
- Revenue
- BIRD $189,757,000.00
- SCYX $3,746,000.00
- Revenue This Year
- BIRD N/A
- SCYX $460.12
- Revenue Next Year
- BIRD $4.60
- SCYX $253.87
- P/E Ratio
- BIRD N/A
- SCYX N/A
- Revenue Growth
- BIRD N/A
- SCYX N/A
- 52 Week Low
- BIRD $3.93
- SCYX $0.73
- 52 Week High
- BIRD $18.34
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- BIRD 48.45
- SCYX 53.61
- Support Level
- BIRD $4.56
- SCYX $0.89
- Resistance Level
- BIRD $5.05
- SCYX $0.99
- Average True Range (ATR)
- BIRD 0.59
- SCYX 0.08
- MACD
- BIRD 0.03
- SCYX 0.01
- Stochastic Oscillator
- BIRD 51.17
- SCYX 91.58
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.